Quick View
| Metric | Current Period | Previous-Year Period | YoY |
|---|---|---|---|
| Revenue | ¥1.7B | ¥3.7B | −54.3% |
| Operating Income | −¥1.2B | −¥0.8B | −59.7% |
| Ordinary Income | −¥1.3B | −¥0.8B | −56.6% |
| Net Income | −¥1.4B | −¥0.8B | −77.6% |
| ROE | −22.8% | −10.6% | - |
Executive Summary
The first quarter of FY2026 was challenging, as Revenue declined significantly and the Company was unable to absorb its fixed-cost burden, resulting in wider operating and net losses. Revenue was ¥1.7B, down 54.3% year on year; Operating Income was ¥-1.2B (versus ¥-0.8B in the previous year); Ordinary Income was ¥-1.3B (versus ¥-0.8B in the previous year); and Net Income was ¥-1.4B (versus ¥-0.8B in the previous year, YoY -77.6%). Although the gross margin was maintained at 30.5%, SG&A expenses reached ¥1.8B, exceeding Revenue and significantly pressuring profitability.
Factors Affecting Performance
【Revenue】Revenue was ¥1.7B, down 54.3% year on year. The primary factor appears to have been fluctuations in project progress and the timing of revenue recognition. This direction differs significantly from the full-year forecast (¥13.8B, +59.0% year on year), and the progress rate was 12.3%, below the standard 25%.
【Profit and Loss】Although the gross margin was maintained at 30.5%, SG&A expenses of ¥1.8B exceeded gross profit of ¥0.5B, causing the operating margin to deteriorate to negative 72.4%. After adding ¥0.1B in non-operating expenses, the ordinary loss widened to ¥1.3B. Including ¥0.04B in extraordinary losses (including losses on disposal of fixed assets), the net loss was ¥1.4B. Even excluding extraordinary losses, the loss at the operating level was the primary factor, indicating that the earnings structure has a recurring problem. The Company reported lower Revenue and lower profit, with insufficient sales scale relative to fixed costs being the largest factor.
Segment Analysis
The segments comprise the Healthcare Solutions Business and the Global Environmental Solutions Business. Total impairment losses for both segments were ¥0.11B (¥0.02B for Healthcare and ¥0.06B for Global Environmental), while ¥0.78B in general and administrative expenses not allocated to the reportable segments as corporate expenses was included in the adjustment amount. Although detailed segment-level Revenue and profit figures were not disclosed, the presence of corporate expenses may be one factor contributing to excessive SG&A expenses.
Key Financial Metrics
【Profitability】The operating margin was negative 72.4% and the net profit margin was negative 79.4%, indicating a significantly loss-making structure. SG&A expenses amounted to 103.1% of Revenue, substantially exceeding the 30.5% gross margin and the scale of Revenue.【Cash Flow Quality】Although Operating Cash Flow was not disclosed, work in process of ¥0.31B accounted for most of inventories of ¥0.40B, raising concerns about working capital being tied up due to delays in project completion and delivery.【Investment Efficiency】ROE was negative 22.8%, primarily due to the deterioration in the net profit margin. Financial leverage (total assets/net assets, approximately 2.21x) itself was not at an extreme level.【Financial Soundness】The Equity Ratio was 45.3% (48.9% in the previous year), the current ratio was 141.3%, and cash and deposits of ¥3.9B accounted for 30.1% of total assets, indicating that short-term liquidity was secured.
Cash Flow Analysis
As figures from the statement of cash flows were not disclosed, cash trends are analyzed based on balance sheet movements. Cash and deposits were ¥3.9B, down from ¥5.6B in the previous year, while net assets declined from ¥7.2B to ¥5.9B. In addition to the recognition of a ¥1.4B net loss, investment securities increased from ¥2.5B to ¥2.7B, suggesting that a portion of funds may have become tied up through investment activities. Accounts receivable increased from ¥0.6B to ¥0.8B, while accounts payable increased from ¥0.2B to ¥0.6B. The increase in operating receivables and payables is likely to place some pressure on working capital. Together with the accumulation of work in process, the potential impact of delayed Revenue recovery on cash management requires monitoring.
Earnings Quality
The current-period loss includes ¥0.04B in extraordinary losses (including ¥0.03B in losses on disposal of fixed assets). However, even excluding these items, the Company incurred an operating loss of ¥1.2B, indicating that the primary cause of the loss was not a temporary factor but a recurring decline in earnings power. Non-operating income was minimal at ¥0.01B, and there is no earnings structure capable of offsetting the loss. Extraordinary income of ¥0.43B had been recorded in the previous-year period but disappeared in the current period, and the reversal of extraordinary items versus the previous year also contributed to the expansion of the net loss. The fact that work in process of ¥0.31B accounts for most of inventories warrants attention from an accrual perspective, as the progress of project completion and conversion into sales will determine the quality of future earnings.
Earnings Forecast and Guidance
The full-year forecast assumes a sharp increase in both Revenue and profit, in contrast to the first-quarter results, with Revenue of ¥13.8B (+59.0% year on year), Operating Income of ¥0.8B, Ordinary Income of ¥0.7B, and Net Income of ¥2.3B. The first-quarter progress rates were 12.3% for Revenue, negative 161.8% for Operating Income due to the recorded loss, and negative 59.7% for Net Income; all were significantly below the standard quarterly progress rate of 25%. To achieve the full-year forecast, the Company must generate cumulative Revenue of ¥12.1B and approximately ¥2.0B in Operating Income over the remaining three quarters, making the plan highly dependent on the second half of the fiscal year.
Shareholder Returns
The full-year dividend forecast is ¥0 per share, unchanged from ¥0 in the previous-year period. As no dividend is expected against forecast Net Income of ¥2.3B, the Payout Ratio is effectively 0%, suggesting a policy of prioritizing the retention of internal funds during the loss-making period. No share repurchases for the current period were disclosed, so the Total Return Ratio cannot be calculated.
Risk Factors
-
Revenue volatility risk: Revenue declined 54.3% year on year, while the direction differs significantly from the full-year forecast (+59.0%). The Company’s performance is structurally highly sensitive to fluctuations in project acquisition, progress, and the timing of revenue recognition.
-
Fixed-cost absorption risk: SG&A expenses of ¥1.75B exceeded Revenue of ¥1.70B, causing the operating margin to deteriorate to negative 72.4%. Losses are likely to expand rapidly when the scale of Revenue falls below fixed costs.
-
Cash management and asset accumulation risk: Current liabilities of ¥7.06B account for the majority of total liabilities, indicating a high degree of dependence on short-term cash management. In addition, work in process of ¥0.31B accounts for most of inventories, and delays in project completion and delivery could delay the conversion of assets into cash.
Industry Benchmark (Reference; Company Analysis)
Industry Benchmark (trading)
Profitability and Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | −72.4% | – | – |
| Net Profit Margin | −79.4% | 7.4% (6.8%–7.9%) | −86.8pt |
The Company’s net profit margin is significantly below the industry median and ranks among the lowest in the industry.
Growth and Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (Year on Year) | −54.3% | 3.8% (0.9%–6.4%) | −58.1pt |
The Revenue growth rate is also significantly below the industry median, indicating that the Company is underperforming the industry in terms of growth.
※Source: Company compilation
Key Points in the Financial Results
-
The central focus in evaluating performance is whether Revenue can recover from Q2 onward and whether the Company can absorb SG&A expenses of approximately ¥1.75B while maintaining the 30.5% gross margin. Achieving the full-year Operating Income forecast requires an improvement of approximately ¥2.0B in cumulative Operating Income over the remaining three quarters, representing a substantial change from the current position.
-
The delivery and conversion into sales of ¥0.31B in work in process, as well as the collection status of ¥0.81B in accounts receivable, are worth monitoring in future financial results as indicators of working capital quality.
-
The ¥0 dividend forecast is positioned as a cash preservation measure during the loss-making period. Given accumulated losses reflected in retained earnings of negative ¥40.16B, the resumption of shareholder returns will be contingent on confirming the sustainability of a recovery in performance.
This report is a financial results analysis document automatically generated by AI based on XBRL financial results summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly available financial results data. Investment decisions should be made at your own responsibility, after consulting professionals as necessary.
---End of Report---
AI Financial Analysis
Executive Summary
FY2026 Q1 was materially weak, with a sharp revenue contraction and a substantially wider operating loss. Revenue fell 54.3% YoY to ¥170 million. Operating loss widened to ¥123 million from a ¥77 million loss in the prior-year quarter. Net loss expanded to ¥135 million from ¥76 million, and loss per share increased to ¥10.44 from ¥7.17. Gross profit declined 35.5% YoY to ¥51.8 million, although the gross margin improved to 30.5% from 21.5% in the prior-year quarter, an improvement of approximately 900bp. The gross-margin improvement was insufficient to offset the severe revenue shortfall. SG&A expenses increased 11.4% YoY to ¥175.3 million despite the revenue decline. As a result, SG&A represented 103.1% of revenue, versus 42.2% a year earlier. The operating margin therefore deteriorated by approximately 5,180bp to negative 72.3% from negative 20.6%. Ordinary loss was ¥130 million, broadly reflecting the operating loss because net non-operating expenses were limited. Net loss was also affected by ¥4.1 million of extraordinary losses, including a ¥3.0 million loss on disposal of fixed assets. The balance sheet retains positive equity of ¥593 million and a current ratio of 141.3%, but equity declined 17.3% YoY as recurring losses continued. Cash and deposits decreased 29.9% YoY to ¥394.3 million, reducing the buffer against continued losses. The full-year plan calls for revenue of ¥1,377 million, operating income of ¥76 million, and net income of ¥226 million, implying a pronounced recovery in the remaining quarters. Q1 revenue progress was only 12.3% of the full-year forecast, below the standard first-quarter pace of 25%, while the company has already recorded an operating loss against a full-year profit target. Achieving the plan will require a major acceleration in sales conversion, sustained gross-margin discipline, and a sharp reduction in fixed-cost intensity. The investment case is consequently centered on the credibility and timing of the planned earnings turnaround rather than current-period profitability.
Profitability Analysis
The reported annualized DuPont ROE was negative 91.1%, decomposed into a negative 79.4% net profit margin, 0.520x asset turnover, and 2.21x financial leverage. The dominant negative driver was the net margin: the operating margin was negative 72.3%, far below the level required to support profitability. Asset turnover was also weak, reflecting the substantial decline in quarterly sales relative to the asset base. Financial leverage magnified the negative return on equity rather than supporting shareholder returns. Revenue fell ¥203 million YoY, whereas SG&A rose by approximately ¥17.9 million, demonstrating pronounced negative operating leverage. The company did achieve a gross-margin improvement of roughly 900bp to 30.5%, indicating that pricing, product mix, or project-level profitability was better than in the prior-year quarter. However, gross profit of ¥51.8 million was only 29.6% of SG&A expense, leaving the cost base structurally too high for the Q1 revenue run-rate. The annualized ROIC quality alert of negative 247.6% similarly indicates very poor returns on invested capital, caused principally by the operating loss rather than a high financing burden. The annualized EBIT margin of negative 72.3% is the specific root cause of the low-operating-efficiency alert; this level of loss indicates that the existing revenue base cannot absorb corporate and operating overhead. The segment disclosure identifies unallocated corporate costs of ¥77.8 million, equal to approximately 45.6% of quarterly revenue, highlighting the importance of overhead rationalization. The deterioration appears primarily operational and recurring at the Q1 sales level, rather than driven by material non-operating costs. The ¥4.1 million extraordinary loss is modest relative to the ¥123 million operating loss and does not explain the core earnings weakness. A sustainable recovery requires revenue growth substantially ahead of SG&A growth, because the present cost structure produces outsized margin volatility.
Growth Assessment
Revenue contracted 54.3% YoY to ¥170 million, indicating that the immediate issue is demand, project timing, or sales execution rather than gross-margin erosion. The improved gross margin provides some evidence that the revenue mix was not uniformly unfavorable. Nevertheless, the absolute gross-profit pool declined by approximately ¥28.5 million YoY and could not support the increased SG&A burden. The full-year revenue forecast of ¥1,377 million implies 59.0% YoY growth for the full year. Q1 revenue represents only 12.3% of that target, a 12.7 percentage-point shortfall versus the conventional 25% first-quarter progress rate. Q1 operating income was negative ¥123 million versus a full-year operating-income forecast of positive ¥76 million. This means the company must generate at least ¥199 million of aggregate operating profit over Q2-Q4 merely to meet the stated annual target. Q1 net loss of ¥135 million also contrasts with a full-year net-income forecast of ¥226 million, requiring a substantial positive reversal over the remaining nine months. The wide gap between the operating-income target and the net-income target suggests that the full-year net-income plan includes meaningful non-operating, extraordinary, or tax-related contributions relative to operating profit. The revenue outlook should therefore be assessed through quarterly order conversion, the scale and timing of healthcare and environmental solution projects, and the pace at which corporate costs are absorbed. Work in process was ¥30.7 million, representing most of total inventory of ¥39.6 million, which may provide a limited pipeline for revenue recognition when projects are completed. However, the high work-in-process composition also creates execution and timing risk if projects are delayed or require additional cost.
Financial Health
Liquidity is adequate but not robust. Current assets were ¥997.8 million against current liabilities of ¥706.2 million, producing a current ratio of 141.3% and positive working capital of ¥291.7 million. The quick ratio was also 135.7%, indicating that stated short-term liquidity is not dependent on inventory realization. Cash and deposits of ¥394.3 million covered only 55.8% of current liabilities, so liquidity depends partly on the collection of receivables, investment liquidity, and management of current obligations. Current liabilities were heavily influenced by ¥374.3 million of suspense payments, making the composition and settlement timing of this balance relevant to near-term liquidity management. Accounts receivable increased 34.4% YoY to ¥81.0 million, while trade payables increased 209.2% YoY to ¥59.1 million. The increase in payables may partly support working capital, but it should be monitored alongside the severe revenue contraction. Total liabilities were ¥714.5 million and total equity was ¥593.0 million, corresponding to a debt-to-equity ratio of 1.20x. This is above a conservative 1.0x level but below the 2.0x threshold for aggressive leverage. Current liabilities account for 98.8% of total liabilities, creating a maturity concentration, although current assets exceed current liabilities by ¥291.7 million. The reported interest-coverage ratio of negative 5,590.91x triggers the debt-service alert because EBIT is deeply negative; the ratio is not evidence of high cash interest costs, as interest expense was only ¥0.02 million, but it confirms that operating earnings do not provide debt-service capacity. Equity fell from ¥717 million to ¥593 million YoY, primarily reflecting loss accumulation, and retained earnings were negative ¥4,015.9 million. Investment securities totaled ¥274.0 million, or 21.0% of total assets, representing a material non-operating asset concentration that could affect balance-sheet resilience through valuation movements. No substantial goodwill or intangible-asset concentration is indicated, with intangible assets representing only 0.1% of total assets.
Notable B/S Changes
Cash and deposits: -¥168.4 million (-29.9% YoY) to ¥394.3 million - cash resources declined alongside the quarterly net loss, reducing the buffer for continued operating losses and working-capital needs. Accounts payable: +¥40.0 million (+209.2% YoY) to ¥59.1 million - supplier financing increased materially and should be monitored against payment terms and project activity. Inventories: +¥22.1 million (+126.6% YoY) to ¥39.6 million - inventory increased despite lower revenue and is concentrated in work in process, increasing project completion and conversion risk. Accounts receivable: +¥20.7 million (+34.4% YoY) to ¥81.0 million - receivables rose despite the revenue contraction, increasing collection and working-capital monitoring importance. Intangible assets: -¥1.1 million (-42.3% YoY) to ¥1.4 million - immaterial to the overall balance sheet and does not indicate meaningful intangible-asset concentration.
Cash Flow Quality
The reported period does not provide operating, investing, or financing cash-flow figures, so cash conversion, free cash flow, and operating-cash-flow-to-net-income coverage cannot be quantified. Balance-sheet movements nonetheless indicate that cash and deposits declined by ¥168.4 million YoY to ¥394.3 million while the company recorded a ¥135 million quarterly net loss. Receivables increased by ¥20.7 million YoY and inventories increased by ¥22.1 million YoY, which increases capital tied up in operating assets despite lower revenue. Trade payables increased by ¥40.0 million YoY, partly offsetting the increase in receivables and inventory from a working-capital funding perspective. Inventory consists predominantly of work in process: the reported quality alert classifies WIP as 100.0% of inventory, while the stated balance-sheet amounts indicate WIP of ¥30.7 million against total inventories of ¥39.6 million. The root cause of the high-WIP-ratio alert is the concentration of inventory in unfinished projects rather than readily saleable completed goods. This may be normal for project-based healthcare and environmental solution activities, but it raises execution, acceptance, and revenue-recognition timing risk. The impact is that additional project delays or cost overruns could defer revenue and require further working capital while the fixed-cost base remains elevated. The cash balance decline and continuing operating loss make preservation of cash resources a central financial discipline issue.
Dividend Sustainability
No dividend was paid in the prior period, and the full-year forecast also indicates a dividend per share of ¥0.00. Accordingly, there is no current cash-dividend commitment to assess through payout ratio or free-cash-flow coverage. The absence of a dividend is consistent with the quarterly net loss of ¥135 million, negative retained earnings of ¥4,015.9 million, and the need to preserve liquidity during the planned earnings recovery. Any future shareholder distribution capacity would depend first on restoring recurring operating profitability and stabilizing cash resources. The stated full-year forecast of ¥226 million in net income would improve earnings capacity if achieved, but the Q1 loss makes the timing and quality of such recovery particularly important.
Risk Assessment
Business risks include Revenue-conversion risk: Q1 sales declined 54.3% YoY, and meeting the ¥1,377 million full-year revenue forecast requires a major acceleration in the remaining quarters., Fixed-cost absorption risk: SG&A rose 11.4% YoY despite lower sales, producing a negative 72.3% operating margin and demonstrating substantial negative operating leverage., Project execution risk: work in process of ¥30.7 million represents the predominant share of inventory, exposing the company to completion delays, customer acceptance risk, and potential cost overruns., Healthcare and environmental solution demand risk: project-based spending cycles, procurement timing, and customer budget constraints can create material volatility in quarterly revenue recognition..
Financial risks include Liquidity-buffer risk: cash and deposits declined 29.9% YoY to ¥394.3 million while the company remained loss-making., Current-liability concentration risk: ¥706.2 million of liabilities are current, although current assets exceed current liabilities and the current ratio remains above 1.0x., Debt-service capacity risk: the negative 5,590.91x interest-coverage ratio reflects negative EBIT and means operating profit currently cannot support financing obligations, despite immaterial reported interest expense., Capital-erosion risk: total equity declined 17.3% YoY to ¥593 million and retained earnings remain deeply negative., Investment-security valuation risk: investment securities account for 21.0% of total assets, making equity sensitive to market-price movements or impairment of these holdings..
Key concerns include High likelihood/high impact: the company must reverse a ¥123 million Q1 operating loss and generate at least ¥199 million of operating profit over Q2-Q4 to achieve the full-year operating-income forecast of ¥76 million., High likelihood/high impact: the annualized ROIC alert of negative 247.6% reflects a severely unproductive capital base under the current earnings run-rate; the immediate priority is restoring operating profitability., Medium likelihood/high impact: the high-WIP-ratio alert signals that a large portion of inventory depends on project completion and conversion into recognized revenue., Medium likelihood/medium impact: the ¥77.8 million quarterly unallocated corporate-cost burden limits the ability of segment gross profit to translate into consolidated operating earnings., Medium likelihood/medium impact: further cash depletion would narrow the financial flexibility available to absorb project delays or continued operating losses..
Investment Implications
Key takeaways include Gross margin improved by approximately 900bp YoY to 30.5%, but the improvement was overwhelmed by a 54.3% revenue decline and an 11.4% increase in SG&A., The central earnings issue is fixed-cost absorption: SG&A exceeded revenue and generated a negative 72.3% operating margin., The balance sheet remains liquid on a current-ratio basis at 141.3%, but cash declined to ¥394.3 million and equity fell to ¥593 million., The FY2026 forecast embeds a highly back-end-loaded recovery, with Q1 revenue progress of 12.3% versus a standard 25% pace and a large required profit reversal., Work-in-process concentration and investment-security exposure are important balance-sheet and execution considerations..
Metrics to watch include Quarterly revenue progress against the ¥1,377 million full-year forecast, Operating-margin recovery and the relationship between SG&A growth and revenue growth, Conversion of ¥30.7 million work in process into completed and recognized revenue, Cash and deposits, current-liability settlement, and movements in receivables and trade payables, Equity trend, retained-loss trajectory, and valuation changes in ¥274.0 million of investment securities, Delivery against the ¥76 million operating-income and ¥226 million net-income full-year forecasts.
Regarding relative positioning, Relative to conventional profitability and capital-efficiency benchmarks, the company is currently positioned well below acceptable levels because of a negative 72.3% EBIT margin, negative 91.1% annualized ROE, and negative 247.6% annualized ROIC. Its liquidity ratios are above warning thresholds, but the operating profile is substantially weaker than that of a financially self-funding business. The improved gross margin is a constructive operating datapoint, yet sustained sales recovery and corporate-cost absorption are required before relative earnings quality can improve.